L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 6.8 NOK -0.29% Market Closed
Market Cap: 337.4m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Lytix Biopharma AS
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lytix Biopharma AS
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
L
Lytix Biopharma AS
OSE:LYTIX
Total Liabilities & Equity
kr63.9m
CAGR 3-Years
25%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Total Liabilities & Equity
kr365.3m
CAGR 3-Years
-6%
CAGR 5-Years
2%
CAGR 10-Years
5%
B
Bergenbio ASA
OSE:BGBIO
Total Liabilities & Equity
kr194.7m
CAGR 3-Years
-28%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Total Liabilities & Equity
kr341.8m
CAGR 3-Years
9%
CAGR 5-Years
35%
CAGR 10-Years
12%
N
Nykode Therapeutics ASA
OSE:NYKD
Total Liabilities & Equity
$179.9m
CAGR 3-Years
-5%
CAGR 5-Years
36%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Total Liabilities & Equity
kr320.1m
CAGR 3-Years
-14%
CAGR 5-Years
-9%
CAGR 10-Years
18%
No Stocks Found

Lytix Biopharma AS
Glance View

Market Cap
337.4m NOK
Industry
Biotechnology

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

LYTIX Intrinsic Value
0.9 NOK
Overvaluation 87%
Intrinsic Value
Price
L

See Also

What is Lytix Biopharma AS's Total Liabilities & Equity?
Total Liabilities & Equity
63.9m NOK

Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Total Liabilities & Equity amounts to 63.9m NOK.

What is Lytix Biopharma AS's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
2%

Over the last year, the Total Liabilities & Equity growth was -58%. The average annual Total Liabilities & Equity growth rates for Lytix Biopharma AS have been 25% over the past three years , 2% over the past five years .

Back to Top